代谢综合征和 2 型糖尿病患者冠状动脉粥样硬化性心脏病相关心外膜脂肪中的炎症基因：与吡格列酮相关的变化。
Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone.
机构信息
Department of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
出版信息
Diabetes Care. 2011 Mar;34(3):730-3. doi: 10.2337/dc10-2083. Epub 2011 Feb 2.
OBJECTIVE
To determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy.
RESEARCH DESIGN AND METHODS
Genes were quantified by RT-PCR in EAT and thoracic subcutaneous adipose tissue (SAT) obtained during surgery in CAD patients with metabolic syndrome (MS) or type 2 diabetes and control subjects with minimal or no CAD and no MS or type 2 diabetes.
RESULTS
Increased expression of interleukin-1 receptor antagonist (IL-1Ra) and IL-10, a trend for higher IL-1β, and no change in peroxisome proliferator-activated receptor-γ (PPARγ) was found in EAT from MS or type 2 diabetes. Only PPARγ mRNA was reduced in SAT. Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT.
CONCLUSIONS
In MS and type 2 diabetes with CAD, proinflammatory and anti-inflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment.
目的
确定与冠状动脉粥样硬化（CAD）相关的心脏外膜脂肪组织（EAT）中基因表达的变化，以及吡格列酮治疗的影响。
研究设计和方法
在患有代谢综合征（MS）或 2 型糖尿病的 CAD 患者以及有最小或无 CAD 且无 MS 或 2 型糖尿病的对照者手术期间获得 EAT 和胸皮下脂肪组织（SAT），通过 RT-PCR 定量基因表达。
结果
在 MS 或 2 型糖尿病患者的 EAT 中发现白细胞介素-1 受体拮抗剂（IL-1Ra）和 IL-10 表达增加，IL-1β 呈上升趋势，过氧化物酶体增殖物激活受体-γ（PPARγ）无变化；而 SAT 中仅 PPARγ mRNA 减少。2 型糖尿病患者的吡格列酮治疗与 EAT 中 IL-1β、IL-1Ra 和 IL-10 表达降低，SAT 中 IL-10 降低以及 SAT 中 PPARγ 增加有关。
结论
在患有 CAD 的 MS 和 2 型糖尿病中，EAT 中促炎和抗炎基因表达不同，与吡格列酮治疗相关的基因表达选择性降低。
Zotero 插件